Several studies show beneficial effects of blocking IL-6 in cancer, especially when IL-6 and/or IL-6R expression are high,44,45,46 indicating that selecting the cancer type is an important factor to effectively benefit from preventing IL-6-mediated pro-tumor effects, such as tumor-induced CD14+ cDC2s, while limiting unwanted side effects as result of the absence of IL-6-mediated anti-tumor effects. This evidence concerns the gene IL6 and neoplasm.